Literature DB >> 1462002

Tubular injury and regeneration in the rat kidney following acute exposure to gentamicin: a time-course study.

D Nonclercq1, S Wrona, G Toubeau, J Zanen, J A Heuson-Stiennon, R P Schaudies, G Laurent.   

Abstract

Aminoglycoside antibiotics act as nephrotoxic drugs, inducing a lysosomal phospholipidosis and necrotic lesions essentially in convoluted proximal tubules. Previous studies have demonstrated that tubular injury caused by these compounds elicits a process of renal tissue repair (tubular regeneration) involving an increase of cell turnover in tubular epithelium. The present study was performed in order to: (i) achieve further insight into the temporal relationship between aminoglycoside-induced phospholipidosis, tubular necrosis, and tubular regeneration; and (ii) approach the control of tubular regeneration after nephrotoxin-induced insult. To investigate the latter point, we examined by immunocytochemistry the intrarenal distribution of epidermal growth factor (EGF) during tubular regeneration. Five groups of female Sprague-Dawley rats (n = 5) were treated for 4 days with gentamicin i.p. at a daily dose of 50 mg/kg delivered in 2 injections per day. Sham-treated animals (n = 5) received an equivalent amount of vehicle (0.9% NaCl) according to the same protocol. Groups of treated rats, and controls, were terminated 16 h (day 1), 4 days, 7 days, 14 days, and 21 days after the end of gentamicin administration. One hour prior to necropsy, each animal was given an i.p. injection of 40 mg 5-bromo-2'-deoxyuridine (BrdU) for the immunocytochemical demonstration of S-phase cells, using an anti-BrdU monoclonal antibody. Renal tissue was processed for light microscopy analysis, namely: a computer-aided morphometry of lysosomes in proximal tubular cells, a single-blind evaluation of gentamicin-induced tubular injury, the measurement of cell proliferation by immunocytochemical detection of BrdU-labeled nuclei, the demonstration of EGF-like immunoreactive material in renal tissue by using anti-rat EGF antiserum and immunogold-silver staining. As revealed by the morphometry of lysosomes in proximal tubular epithelium, the degree of gentamicin-induced phospholipidosis was maximum at day 1 (relative area occupied by lysosomes was increased 25-fold over mean control value) and declined thereafter. In contrast, tubular necrosis reached a peak 4 days after the end of drug administration. In proximal tubular epithelium, the stimulation of cell turnover associated with tubular regeneration showed a peak at day 7 (15-fold the mean control value). Tubular regeneration was also accompanied by mild interstitial hyperplasia. Three weeks after treatment with gentamicin, morphological evidence of drug-induced injury had disappeared due to the tissue repair process, except for the occasional presence of small hyperplastic foci in renal cortex interstitium. In both treated animals and controls, EGF immunoreactivity as revealed by immunocytochemical staining was associated with distal tubules (renal cortex and outer medulla).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1462002     DOI: 10.3109/08860229209047660

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  10 in total

1.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Genome-Scale Model-Based Identification of Metabolite Indicators for Early Detection of Kidney Toxicity.

Authors:  Venkat R Pannala; Kalyan C Vinnakota; Shanea K Estes; Irina Trenary; Tracy P OˈBrien; Richard L Printz; Jason A Papin; Jaques Reifman; Tatsuya Oyama; Masakazu Shiota; Jamey D Young; Anders Wallqvist
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

Review 3.  Intracellular mechanisms of aminoglycoside-induced cytotoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Integr Biol (Camb)       Date:  2011-07-29       Impact factor: 2.192

4.  Systemic Fluorescent Gentamicin Enters Neonatal Mouse Hair Cells Predominantly Through Sensory Mechanoelectrical Transduction Channels.

Authors:  Ayane Makabe; Yoshiyuki Kawashima; Yuriko Sakamaki; Ayako Maruyama; Taro Fujikawa; Taku Ito; Kiyoto Kurima; Andrew J Griffith; Takeshi Tsutsumi
Journal:  J Assoc Res Otolaryngol       Date:  2020-03-09

5.  Uptake of fluorescent gentamicin by vertebrate sensory cells in vivo.

Authors:  C F Dai; D Mangiardi; D A Cotanche; P S Steyger
Journal:  Hear Res       Date:  2006-02-08       Impact factor: 3.208

6.  Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.

Authors:  Meiyan Jiang; Qi Wang; Takatoshi Karasawa; Ja-Won Koo; Hongzhe Li; Peter S Steyger
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 7.  How much can the tubule regenerate and who does it? An open question.

Authors:  Duccio Lombardi; Francesca Becherucci; Paola Romagnani
Journal:  Nephrol Dial Transplant       Date:  2015-07-13       Impact factor: 5.992

Review 8.  Gentamicin nephrotoxicity in animals: Current knowledge and future perspectives.

Authors:  Pavle Randjelovic; Slavimir Veljkovic; Nenad Stojiljkovic; Dušan Sokolovic; Ivan Ilic
Journal:  EXCLI J       Date:  2017-03-24       Impact factor: 4.068

9.  Arid3a regulates nephric tubule regeneration via evolutionarily conserved regeneration signal-response enhancers.

Authors:  Nanoka Suzuki; Kodai Hirano; Hajime Ogino; Haruki Ochi
Journal:  Elife       Date:  2019-01-08       Impact factor: 8.140

10.  Sidt2 is a key protein in the autophagy-lysosomal degradation pathway and is essential for the maintenance of kidney structure and filtration function.

Authors:  Meng-Ya Geng; Lizhuo Wang; Ying-Ying Song; Jing Gu; Xin Hu; Cheng Yuan; Meng Yang; Wen-Jun Pei; Yao Zhang; Jia-Lin Gao
Journal:  Cell Death Dis       Date:  2021-12-18       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.